



Neurotech announces return of founder as strategic advisor

- *Dr Attard Trevisan to advise on Neurotech's focus on medical and artificial intelligence*

Perth, Australia & Malta – 20 December 2018 – Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”) is pleased to announce that Dr Adrian Attard Trevisan, the founder and visionary of the Mente therapy for Autism, will return to the Company as a strategic advisor with particular focus on medical and artificial intelligence.

Dr Attard Trevisan founded AAT Research, the Malta-based subsidiary of Neurotech International Ltd, in 2013 and was instrumental in driving the Company’s growth and successful listing on the Australian Stock Exchange. He formed part of the Board at Neurotech as a non-executive director until July of 2018. He was also chair of the Scientific Advisory Board.

Neurotech CEO Peter Griffiths said: “I am very pleased that Adrian will re-engage with the Company. Adrian is busy working on new opportunities in the medical sector but working with us in an advisory capacity will allow him to provide key input and support to our initiatives and maintain oversight on Neurotech’s progress. I greatly value the insight and energy that Adrian brings to the business and look forward to a fruitful and long-last partnership that will build value for all.”

Dr Attard Trevisan said: “I am very pleased to participate again in this very exciting company with a huge potential for growth and innovation. Peter and I are aligned on the key elements of the vision he is setting for the Company and we will keep a healthy debate open on the opportunities and challenges that lie ahead. I am excited and looking forward to working with Peter and his team once again.”

Neurotech said Dr Attard Trevisan has signed a consulting agreement with the Company and as a strategic advisor will be subject to normal insider trading restrictions. Dr Attard Trevisan has also announced that has no intention of selling further shares over the year ahead and a sign of support has agreed that he will receive remuneration for services provided in the form of shares in lieu of cash.

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with autism spectrum disorder. Designed for home use, it helps relax the minds of children on the spectrum which in turn helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

Media enquiries

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420